Literature DB >> 7520474

Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia.

K Kojima1, T Berger, H Lassmann, D Hinze-Selch, Y Zhang, J Gehrmann, K Reske, H Wekerle, C Linington.   

Abstract

The pathogenic potential of autoimmune T cell responses to nonmyelin autoantigens was investigated in the Lewis rat using the astrocyte-derived calcium binding protein S100 beta, as a model nonmyelin autoantigen. The Lewis rat mounts a vigorous RT1B1 (major histocompatibility complex class II) restricted autoimmune response to an immunodominant S100 beta epitope (amino acid residues 76-91). The adoptive transfer of S100 beta-specific T cell lines induced a severe inflammatory response in the nervous system, but only minimal neurological dysfunction in naive syngeneic recipients. The inability of S100 beta-specific T cell transfer to induce severe disease was associated with a decreased recruitment of ED1+ macrophages into the central nervous system (CNS) in comparison with that seen in severe experimental autoimmune encephalomyelitis (EAE) induced by the adoptive transfer of myelin basic protein (MBP)-specific T line cells. Moreover, unlike encephalitogenic MBP-specific T cell lines, S100 beta-specific T cell lines exhibited no cytotoxic activity in vitro. Histopathological analysis also revealed striking differences in the distribution of inflammatory lesions in MBP- and S100 beta-specific T cell-mediated disease. In contrast to the MBP paradigm, S100 beta-specific T cell transfer induces intense inflammation not only in the spinal cord, but throughout the entire CNS and also in the uvea and retina of the eye. In view of the distribution of lesions throughout the grey and white matter of the CNS we propose to term this new model experimental autoimmune panencephalomyelitis (EAP) to differentiate it from EAE. These experiments demonstrate for the first time that nonmyelin CNS autoantigens can initiate a pathogenic autoimmune T cell response, although the nature of the target autoantigen profoundly influences the clinical and histopathological characteristics of the resulting autoimmune disease. This is not simply a consequence of the distribution of the autoantigen, as both MBP and S100 beta are coexpressed in many areas of the CNS, but reflects differences in the capacity of different regions of the CNS to process and present specific autoantigens. This new model of T cell-mediated autoimmune CNS disease exhibits a number of similarities to multiple sclerosis (MS), such as its mild clinical course and the involvement of areas of the brain and eye, which are absent in myelin-mediated models of EAE. Nonmyelin autoantigens may therefore play an unexpectedly important role in the immunopathogenesis of inflammatory diseases of the CNS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520474      PMCID: PMC2191664          DOI: 10.1084/jem.180.3.817

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  53 in total

1.  [Clinical & experimental research findings in multiple sclerosis].

Authors:  H TSCHABITSCHER
Journal:  Wien Z Nervenheilkd Grenzgeb       Date:  1958

2.  A new monoclonal antibody, TRPM-3, binds specifically to certain rat macrophage populations: immunohistochemical and immunoelectron microscopic analysis.

Authors:  M Takeya; L Hsiao; K Takahashi
Journal:  J Leukoc Biol       Date:  1987-03       Impact factor: 4.962

3.  Chronic periphlebitis retinae in multiple sclerosis. A histopathological study.

Authors:  P J Shaw; N M Smith; P G Ince; D Bates
Journal:  J Neurol Sci       Date:  1987-02       Impact factor: 3.181

4.  Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis.

Authors:  S Lightman; W I McDonald; A C Bird; D A Francis; A Hoskins; J R Batchelor; A M Halliday
Journal:  Brain       Date:  1987-04       Impact factor: 13.501

5.  A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease.

Authors:  H J Schluesener; R A Sobel; C Linington; H L Weiner
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

6.  The distribution of Ia antigen in the lesions of rat acute experimental allergic encephalomyelitis.

Authors:  K Vass; H Lassmann; H Wekerle; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

7.  Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein.

Authors:  C Linington; M Bradl; H Lassmann; C Brunner; K Vass
Journal:  Am J Pathol       Date:  1988-03       Impact factor: 4.307

8.  Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention.

Authors:  H Acha-Orbea; D J Mitchell; L Timmermann; D C Wraith; G S Tausch; M K Waldor; S S Zamvil; H O McDevitt; L Steinman
Journal:  Cell       Date:  1988-07-15       Impact factor: 41.582

9.  Characterization of human brain S100 protein fraction: amino acid sequence of S100 beta.

Authors:  R Jensen; D R Marshak; C Anderson; T J Lukas; D M Watterson
Journal:  J Neurochem       Date:  1985-09       Impact factor: 5.372

10.  Experimental allergic encephalomyelitis in the absence of a classical delayed-type hypersensitivity reaction. Severe paralytic disease correlates with the presence of interleukin 2 receptor-positive cells infiltrating the central nervous system.

Authors:  J Sedgwick; S Brostoff; D Mason
Journal:  J Exp Med       Date:  1987-04-01       Impact factor: 14.307

View more
  35 in total

Review 1.  Therapeutic strategies in multiple sclerosis. I. Immunotherapy.

Authors:  R Hohlfeld
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

2.  Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients.

Authors:  H Fukaura; S C Kent; M J Pietrusewicz; S J Khoury; H L Weiner; D A Hafler
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

3.  Electroretinographic abnormalities in multiple sclerosis: possible role for retinal autoantibodies.

Authors:  Farzin Forooghian; Melanie Sproule; Carol Westall; Lynn Gordon; Guy Jirawuthiworavong; Kaori Shimazaki; Paul O'Connor
Journal:  Doc Ophthalmol       Date:  2006-09-14       Impact factor: 2.379

Review 4.  Autoimmune modulation of astrocyte-mediated homeostasis.

Authors:  Thomas Korn; Mahendra Rao; Tim Magnus
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 5.  Cortical, subcortical and spinal alterations in neuroimmunological diseases.

Authors:  Hans Lassmann
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

6.  T-cell apoptosis in inflammatory brain lesions: destruction of T cells does not depend on antigen recognition.

Authors:  J Bauer; M Bradl; W F Hickley; S Forss-Petter; H Breitschopf; C Linington; H Wekerle; H Lassmann
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

Review 7.  Immune control of the brain.

Authors:  M Bradl
Journal:  Springer Semin Immunopathol       Date:  1996

8.  Immunology: Licensed in the lungs.

Authors:  Richard M Ransohoff
Journal:  Nature       Date:  2012-08-30       Impact factor: 49.962

9.  Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat.

Authors:  T Smith; A K Hewson; C I Kingsley; J P Leonard; M L Cuzner
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

10.  Polyreactive myelin oligodendrocyte glycoprotein antibodies: Implications for systemic autoimmunity in progressive experimental autoimmune encephalomyelitis.

Authors:  Lisa K Peterson; Ikuo Tsunoda; Takahisa Masaki; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2007-01-02       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.